Market Place
Sourcing Support
DiaMedica Gets Approval For Phase 2 DM199 Preeclampsia Trial
09 Oct 2024 //
BUSINESSWIRE
DiaMedica Therapeutics Upcoming Conference Participation
04 Sep 2024 //
BUSINESSWIRE
DiaMedica Therapeutics Reports Q2 2024 Results And Provides Business Update
07 Aug 2024 //
BUSINESSWIRE
DiaMedica To Report Q2 2024 Results On August 8
01 Aug 2024 //
BUSINESSWIRE
DiaMedica Releases Preeclampsia White Paper And Announces KOL Webinar
11 Jul 2024 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
01 Jul 2024 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Expansion Of Rinvecalinase AlfaProgram
26 Jun 2024 //
BUSINESSWIRE
DiaMedica Therapeutics Announces $11.8 Million Private Placement
26 Jun 2024 //
BUSINESSWIRE
Diamedica Therapeutics: Business Update, Q1 2024 Financials
08 May 2024 //
BUSINESSWIRE
DiaMedica To Report Q1 2024 Results, Business Update On May 9
02 May 2024 //
BUSINESSWIRE
DiaMedica Provides a Business Update & Announces Full Year 2023 FYR
19 Mar 2024 //
BUSINESSWIRE
DiaMedica Announces Poster Presentation at International Stroke Conference
29 Jan 2024 //
BUSINESSWIRE
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
22 Jan 2024 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Third Quarter 2023 Financial Results
13 Nov 2023 //
BUSINESSWIRE
DiaMedica to Attend the 14th Annual Craig-Hallum Alpha Select Conference
09 Nov 2023 //
BUSINESSWIRE
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results
06 Nov 2023 //
BUSINESSWIRE
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah as CTO
12 Sep 2023 //
BUSINESSWIRE
DiaMedica to Participate at Lake Street’s 7th Annual Best Ideas Conference
06 Sep 2023 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Second Quarter 2023 Financial Results
14 Aug 2023 //
BUSINESSWIRE
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
DiaMedica to Attend the American Academy of Neurology Summer Conference
18 Jul 2023 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
26 Jun 2023 //
BUSINESSWIRE
Bluebird gets PDUFA date for lovo-cel; FDA lifts hold on DiaMedica stroke trial
21 Jun 2023 //
ENDPTS
DiaMedica Announces that the FDA Has Removed The Clinical Hold On DM199
21 Jun 2023 //
BUSINESSWIRE
DiaMedica Therapeutics Announces $37.5 Million Private Placement
21 Jun 2023 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz BOD
30 May 2023 //
BUSINESSWIRE
DiaMedica prepares to end 10-month stroke hold by halving dose
16 May 2023 //
FIERCE BIOTECH
DiaMedica Therapeutics Provides a Business Update & Announces 1Q 2023 FYR
15 May 2023 //
BUSINESSWIRE
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results
08 May 2023 //
BUSINESSWIRE
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
11 Apr 2023 //
BUSINESSWIRE
DiaMedica Announces Full Year 2022 Financial Results
28 Mar 2023 //
BUSINESSWIRE
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results
20 Mar 2023 //
BUSINESSWIRE
DiaMedica to Present at the Oppenheimer 33rd Annual Healthcare Conference
13 Mar 2023 //
BUSINESSWIRE
DiaMedica Announces the Appointment of Tanya Lewis to Its Board of Directors
06 Mar 2023 //
BUSINESSWIRE
DiaMedica Therapeutics Provides a Business Update and Announces 3Q 2022 Results
09 Nov 2022 //
BUSINESSWIRE
DiaMedica to Attend the 13th Annual Craig-Hallum Alpha Select Conference
07 Nov 2022 //
BUSINESSWIRE
No remedy for DiaMedica as FDA maintains hold on stroke trial
27 Oct 2022 //
FIERCEBIOTECH
DiaMedica Appoints Julie Daves as SVP, Clinical Development Operations
14 Sep 2022 //
BUSINESSWIRE
DiaMedica to Present at Lake Street’s 6th Annual Best Ideas Growth Conference
06 Sep 2022 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Second Quarter 2022 Financial Results
10 Aug 2022 //
BUSINESS WIRE
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
FDA Places Clinical Hold on DiaMedica’s PII/III ReMEDy2 Trial for DM199
14 Jul 2022 //
TRIALSITENEWS
DiaMedica Announces Clinical Hold of its PII/III ReMEDy2 Trial for DM199
06 Jul 2022 //
BUSINESSWIRE
DiaMedica to Attend 19th Annual Craig-Hallum Institutional Investor Conference
25 May 2022 //
BUSINESSWIRE
DiaMedica Therapeutics Announces First Quarter 2022 Financial Results
04 May 2022 //
BUSINESSWIRE
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results
28 Apr 2022 //
BUSINESSWIRE
DiaMedica Tx Announces Fourth Quarter 2021 Financial Results
14 Mar 2022 //
BUSINESSWIRE
DiaMedica Tx to Report Q4 2021 Financial Results and Provide Business Update
08 Mar 2022 //
BUSINESSWIRE
DiaMedica Therapeutics to Present Research at International Stroke Conference
25 Jan 2022 //
BUSINESSWIRE
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
05 Jan 2022 //
BUSINESSWIRE
DiaMedica to Present at the Piper Sandler Healthcare Conference
17 Nov 2021 //
BUSINESSWIRE
DiaMedica Provides Business Update and Announces Q3 2021 Financial Results
10 Nov 2021 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial
18 Oct 2021 //
BUSINESSWIRE
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199
30 Sep 2021 //
BUSINESSWIRE
DiaMedica Therapeutics Initiates Trial of DM199 for Acute Ischemic Stroke
13 Sep 2021 //
BUSINESSWIRE
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
07 Sep 2021 //
BUSINESSWIRE
DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results
05 Aug 2021 //
BUSINESSWIRE
DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology
29 Jul 2021 //
BUSINESSWIRE
DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors
15 Jul 2021 //
BUSINESS WIRE
DiaMedica Therapeutics Announces Interim Results from Phase 2 REDUX Study
29 Jun 2021 //
BUSINESSWIRE
